Increasing use of a new health technology during the wait for NICE guidance: Findings from the third national tracker survey of photodynamic therapy

Journal of Public Health

Volumn 26, Issue 1, 2004, Pages 52-55

  Foot, Barny ^a,b   Foy, Robbie ^c   Chakravarthy, Usha ^d   Wormald, Richard ^b  

^a ROYAL COLLEGE OF OPHTHALMOLOGISTS   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Health technology; Photodynamic therapy; Service provision

Indexed keywords

ADULT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; MEDICAL TECHNOLOGY; NATIONAL HEALTH SERVICE; NATIONAL INSTITUTE FOR CLINICAL EFFECTIVENESS; NORMAL HUMAN; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; VISUAL ACUITY; VISUAL DISORDER;

EID: 2942748301     PISSN: 17413842     EISSN: None     Source Type: Journal    
DOI: 10.1093/pubmed/fdh112     Document Type: Review

References (13)

1. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials. TAP report 1. Arch Ophthalmol 1999; 117: 1329-1345.
2. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001; 119(2): 198-207.
3. Bressler NM. Age-related macular degeneration. New hope for a common problem comes from photodynamic therapy. Br Med J 2000; 821: 1425-1427.
4. NHS delays 'causing blindness'. [On-line.] http://www.news.bbc.co.uk/hi/ english/health/newsid_1678000/1678779.stm.
5. Wormald R, Evans J, Smeeth L. Photodynamic therapy for neovascular age-related macular degeneration (Cochrane review). In: Cochrane Library 1:2001. Oxford: Software Update, 2001.
6. NHS R&D HTA Programme. Clinical effectiveness and cost utility of photodynamic therapy for wet age-related macular degeneration. Birmingham: West Midlands Health Technology Assessment Group, Department of Public Health and Epidemiology, University of Birmingham, 2002.
7. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108(11): 2051-2059.
8. National Institute of Clinical Excellence. Guidance on the use of photodynamic therapy for age related macular degeneration. Technology Appraisal 68. London: NICE, 2003.
9. Foot B, Foy R, Chakravarthy U, Wormald R. A new health technology: where is the consensus on a clinically worthwhile benefit? Eye 2002; 16(4): 469-471.
10. Foot B, Foy R, Chakravarthy U, Wormald R. Introduction of photodynamic therapy for the treatment of age related macular degeneration: tracking a moving target. Eye 2003; 17(5): 583-586.
11. Rosen R, Gabbay J. Linking health technology assessment to practice. Br Med J 1999; 319: 1292.
12. Rogers EM. Diffusion of innovations, 4th edn. New York: The Free Press, 1995.
13. Stevens A, Colin-Jones D, Gabbay J. 'Quick and clean': authoritative health technology assessment for local health care contracting. Hlth Trends 1995; 27(2): 37-42.